Study identifies 20 metabolites related to insulin resistance | Experts use clamp data to develop insulin resistance cutoff | Degludec fares better than glargine in glucose control
April 24, 2012
DiabetesPro SmartBrief
News for diabetes health professionals
SIGN UP ⋅   FORWARD
Diabetes in Focus
Study identifies 20 metabolites related to insulin resistance
Researchers using nuclear magnetic resonance spectroscopy have identified 20 metabolites that are linked to insulin resistance. The study, published in Diabetes, analyzed the metabolic profiles of 7,098 people. "Metabolic signatures extending beyond obesity and lipid abnormalities reflected the degree of insulin resistance evidenced in young, normoglycemic adults with sex-specific fingerprints," the researchers wrote.
Physician's Briefing/HealthDay News/HealthDay News (4/23) 
LinkedIn Twitter Facebook Google+ Email
Experts use clamp data to develop insulin resistance cutoff
Researchers who looked at hyperinsulinemic-euglycemic clamp data found true insulin resistance in 75% of participants with a glucose disposal rate of less than 5.6 mg/kg fat-free mass + 17.7 min. The study in Diabetes Care found the homeostasis model assessment of insulin resistance values showed an 89% sensitivity and 67% specificity in predicting insulin resistance in participants.
Physician's Briefing/HealthDay News/HealthDay News (4/23) 
LinkedIn Twitter Facebook Google+ Email
Degludec fares better than glargine in glucose control
Type 2 diabetes patients who took insulin degludec showed lower rates of overall hypoglycemic episodes per year than their counterparts who received insulin glargine, according to two Phase III studies in The Lancet. Researchers also found that patients with type 1 or type 2 diabetes who were on degludec treatment had a 25% reduction in nocturnal hypoglycemia rates compared with those who took glargine.
Medical News Today (4/23) 
LinkedIn Twitter Facebook Google+ Email
Nutrition & Wellness
Childhood obesity rates drop in Mass.
Obesity prevalence among children younger than 6 in eastern Massachusetts was steady from 1999 to 2003, but significantly dropped from 2004 to 2008, according to a study in Pediatrics. Researchers assessed EMR data of almost 37,000 children from 1999 to 2008 and found that those on Medicaid had smaller declines in obesity prevalence compared with children covered by other health plans.
Physician's Briefing/HealthDay News/HealthDay News (4/23),  The Boston Globe (tiered subscription model) (4/23) 
LinkedIn Twitter Facebook Google+ Email
Stem cell protein may hold promise for obesity treatment
Reducing the amount of endoglin protein on the surface of stem cells curbs the production of fat cells, according to a study presented at the American Society for Biochemistry and Molecular Biology's annual meeting. Research on osteoporosis led to the discovery, which could have applications in treatments for obesity, researchers said.
Examiner.com (4/23) 
LinkedIn Twitter Facebook Google+ Email
Practice Update
EHR incentive payments reach $4.5B for Medicaid, Medicare providers
The CMS has paid $4.5 billion in EHR incentives to 76,612 hospitals and doctors through March. In March, Medicare payments to eligible providers amounted to $339.9 million, while Medicaid incentives paid to professionals and hospitals for adopting, using and upgrading EHRs totaled $254.1 million.
Healthcare IT News (4/20) 
LinkedIn Twitter Facebook Google+ Email
ACP calls for increase in public health funding
The American College of Physicians published a position paper that calls for better funding for public health infrastructure such as medical informatics and staff training, as well as sufficient vaccine and drug supplies. The group said programs that address childhood obesity, smoking, substance abuse, mental illness and health disparities, among others, should receive funding priority.
Modern Healthcare (subscription required) (4/22) 
LinkedIn Twitter Facebook Google+ Email
Trends & Technology
Watson rolls out generic of diabetes drug Fortamet
Watson Pharmaceuticals introduced extended-release metformin hydrochloride, an authorized generic version of Shionogi's type 2 diabetes drug Fortamet. The debut coincides with the relaunch of Lupin's generic Fortamet.
Drug Store News (4/23) 
LinkedIn Twitter Facebook Google+ Email
  
  
There are three cures for ennui: sleep, drink and travel.
D.H. Lawrence,
British novelist
LinkedIn Twitter Facebook Google+ Email
  
  
Learn more about DiabetesPro:
DiabetesPro Home | Professional Education | Journals
Research Grants | Recognition Programs | Membership
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Partner Relations Manager  -  Lauren Barr
Editor  -  Kathryn Doherty
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information